TRVI

Trevi Therapeutics

• TipRanks·4d ago

  Big Pharma Has $1.2 Trillion to Spend and a Revenue Gap to Fill: Inside the F/m Emerald Life Sciences Innovation ETF (LFSC)

• TipRanks·10/22 21:00

  Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Trevi Therapeutics (TRVI)

• NASDAQ·10/12 20:24

  After Hours Most Active for Oct 12, 2026 : NU, CMCSA, INDV, CTRI, NVDA, SNAP, TRVI, TJX, GOOGL, AMZN, CBZ, NOK

• NASDAQ·10/09 20:24

  After Hours Most Active for Oct 9, 2026 : FTXR, NVDA, BKD, GRAB, TRVI, URGN, INDV, LUV, WFC, ESI, OSG, BAC

• TipRanks·10/07 12:40

  Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Trevi Therapeutics (TRVI)

• TipRanks·09/29 19:05

  Trevi Therapeutics management to meet with Cantor

• Seeking Alpha·08/20 05:19

  Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform

• Dow Jones·08/14 13:01

  Trevi Therapeutics Price Target Raised to $28.00/Share From $24.00 by Jones Trading

• Dow Jones·08/14 13:01

  Trevi Therapeutics Is Maintained at Buy by Jones Trading

• TipRanks·08/13 19:35

  Trevi Therapeutics Initiated at Buy on Clean Late-Stage Execution, De-Risked IPF Cough and RCC Pipelines, and Solid Cash Position

• TipRanks·08/11 10:15

  Trevi Therapeutics: Strong Haduvio Execution, Limited Competition Support Buy Rating and Unchanged $24 Price Target

• TipRanks·08/07 21:35

  Trevi Therapeutics: Buy Rating Reiterated on Haduvio’s Cough Program Progress and Strong Cash Runway; $23 Price Target Unchanged

• Dow Jones·08/07 15:31

  Trevi Therapeutics Is Maintained at Outperform by Oppenheimer

• Dow Jones·08/07 15:31

  Trevi Therapeutics Price Target Raised to $25.00/Share From $24.00 by Oppenheimer

• TipRanks·08/07 13:57

  Trevi Therapeutics price target raised to $23 from $20 at Morgan Stanley